Clovis Oncology Inc. [NASDAQ: CLVS] jumped around 0.29 points on Friday, while shares priced at $1.18 at the close of the session, up 31.87%. The company report on June 14, 2022 that Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
First presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity.
Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose.
Clovis Oncology Inc. stock is now -56.46% down from its year-to-date (YTD) trading value. CLVS Stock saw the intraday high of $1.20 and lowest of $0.881 per share. The company’s 52-week high price is 6.65, which means current price is +103.10% above from all time high which was touched on 04/06/22.
Compared to the average trading volume of 13.29M shares, CLVS reached a trading volume of 19198489 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $29 to $33. The new note on the price target was released on May 18, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $5, while SVB Leerink analysts kept a Underperform rating on CLVS stock.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.14, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 0.89.
How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 77.90. With this latest performance, CLVS shares gained by 59.44% in over the last four-week period, additionally sinking by -57.09% over the last 6 months – not to mention a drop of -80.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 61.00, with the RSI for the last a single of trading hit 71.90, and the three-weeks RSI is set at 53.60 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 1.3390, while it was recorded at 0.9103 for the last single week of trading, and 2.6369 for the last 200 days.
Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Insider trade positions for Clovis Oncology Inc. [CLVS]
There are presently around $67 million, or 40.00% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: VANGUARD GROUP INC with ownership of 12,348,898, which is approximately 22.084% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 9,985,759 shares of the stock with an approximate value of $11.78 million in CLVS stocks shares; and PALO ALTO INVESTORS LP, currently with $5.28 million in CLVS stock with ownership of nearly 11.91% of the company’s market capitalization.
Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 82 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 11,643,418 shares. Additionally, 60 investors decreased positions by around 21,259,746 shares, while 39 investors held positions by with 23,540,265 shares. The mentioned changes placed institutional holdings at 56,443,429 shares, according to the latest SEC report filing. CLVS stock had 25 new institutional investments in for a total of 1,429,245 shares, while 24 institutional investors sold positions of 2,307,232 shares during the same period.